Searched for
SUN OPHTHALMICS
Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...- Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...
- Sun Pharma launches novel therapy for dry eye disease in IndiaDED is caused when the quantity or quality of tears fails to keep the surface of the eye properly lubricated, and associated with symptoms ...
- Aurobindo, Sun Pharma recall products in US marketAccording to the latest enforcement report issued by the US Food and Drug Administration (USFDA), the US-based arm of Aurobindo Pharma is r...
- Sun Pharma launches dry eye treatment product in CanadaThe product is the first dry eye treatment available in Canada that is delivered with nanomicellar (NCELL) technology, which improves the b...
- Sun Pharma launches Cequa to treat dry eye disease in USOne of the company's wholly-owned subsidiaries has commercialised Cequa 0.09 per cent in the US, Sun Pharma said in a filing to BSE.
- Local pharma formulators to benefit from new USFDA generic guidance: ReportThis will help domestic pharma formulators with pending ANDA approvals to reduce review cycles and expedite approvals, says a weekend repor...
- Sun Pharma receives USFDA nod ophthalmic solution used to treat dry eye diseaseNew Delhi, Aug 16 () Sun Pharma has received approval from the US health regulator for CEQUA (cyclosporine ophthalmic solution), used to in...
- Sun Pharma climbs 2% on USFDA approvalThe drug in question is CEQUA (cyclosporine ophthalmic solution) 0.09 per cent.
- Sun Pharma climbs 3% after USFDA accepts new drug applicationhares of the company opened at Rs 545 and touched a high and low of Rs 559.30 and Rs 543.15, respectively, in trade so far.
- USFDA accepts Sun Pharma arm's ophthalmic drug applicationSun Pharma said that post the USFDA approval, OTX-101 will be commercialised in the US by Sun Ophthalmics, the branded ophthalmics division...
- Sun Pharma launches first branded drug BromSite in USThe launch marks Sun Pharma’s entry into the branded drugs business in the US, a segment that many generic drug companies are targeting as ...
- Sun Pharma to buy Ocular Technologies from Auven TherapeuticsSun will pay Auven $40 million upfront, contingent development milestones and sales milestones, in addition to royalties on sales of Secier...
- USFDA nod for eyecare drug BromSite gives boost to Sun PharmaThe product will be commercialized through New Jersey-based Sun Ophthalmics, a division that Sun formed recently to route its specialty bra...
- Sun Pharma gets USFDA nod for eye inflammation drugThe company is likely to commercialise BromSite through its newly formed US-based division Sun Ophthalmics in the second half of 2016.
- Sun Pharma completes acquisition of InSite VisionThe company said each issued and outstanding share of InSite common stock... was converted into the right to receive $0.35 as a result of t...
- Sun Pharma makes tender offer to acquire InSite VisionSun Pharmaceutical Industries has made a tender offer to acquire US-based eyecare firm InSite Vision for USD 0.35 per share in cash.
- Sun Pharma plans to buy US-based eye care company InSite VisionSun Pharma said one of its subsidiaries plans to acquire US-based InSite Vision, a company that develops specialty ophthalmic, or eye care ...
- Sun Pharma recalls 5,322 bottles of Ketorolac eye drop in USLast month, the drug major had recalled 3,263 bottles of epilepsy drug in US market for failing "dissolution specifications".
- Sun Pharma Advanced Research Company to file new drug application for opthalmic solution in Q2 FY'14Sun Pharma Advanced Research Company (SPARC) today said it plans to file in the second quarter of the next financial year a new drug applic...
Load More
